Thus, in pediatric and adolescent patients, 4-1BB costimulation in CD19-CAR-T cell therapy may be superior compared to CD28 costimulation for the treatment of B-cell precursor ALL. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.